m6A-centered Drug Response Information
General Information of the Drug (ID: M6ADRUG0256)
| Name |
Salicylic acid derivative 2
|
||||
|---|---|---|---|---|---|
| Synonyms |
PMID26394986-Compound-14
Click to Show/Hide
|
||||
| Structure |
 |
||||
|
3D MOL
|
|||||
| Formula |
C29H27F5N2O6S
|
||||
| InChI |
InChI=1S/C29H27F5N2O6S/c1-35(43(41,42)28-26(33)24(31)23(30)25(32)27(28)34)15-22(38)36(19-11-12-20(29(39)40)21(37)13-19)14-16-7-9-18(10-8-16)17-5-3-2-4-6-17/h7-13,17,37H,2-6,14-15H2,1H3,(H,39,40)
|
||||
| InChIKey |
WNVSFFVDMUSXSX-UHFFFAOYSA-N
|
||||
| PubChem CID | |||||
| TTD Drug ID | |||||
Full List of Crosstalk(s) between m6A Modification and Epigenetic Regulation Related to This Drug
| In total 3 item(s) under this drug | ||
| Crosstalk ID: M6ACROT05958 | ||
| m6A Regulator | Leucine-rich PPR motif-containing protein, mitochondrial (LRPPRC) | |
| m6A Target | Differentiation antagonizing non-protein coding RNA (DANCR) | |
| Epigenetic Regulator | Differentiation antagonizing non-protein coding RNA (DANCR) | |
| Regulated Target | Interleukin-11 (IL11) | |
| Crosstalk relationship | m6A → ncRNA | |
| Disease | Bladder cancer | |
| Crosstalk ID: M6ACROT05959 | ||
| m6A Regulator | Leucine-rich PPR motif-containing protein, mitochondrial (LRPPRC) | |
| m6A Target | Differentiation antagonizing non-protein coding RNA (DANCR) | |
| Epigenetic Regulator | Differentiation antagonizing non-protein coding RNA (DANCR) | |
| Regulated Target | G1/S-specific cyclin-D1 (CCND1) | |
| Crosstalk relationship | m6A → ncRNA | |
| Disease | Bladder cancer | |
| Crosstalk ID: M6ACROT05960 | ||
| m6A Regulator | Leucine-rich PPR motif-containing protein, mitochondrial (LRPPRC) | |
| m6A Target | Differentiation antagonizing non-protein coding RNA (DANCR) | |
| Epigenetic Regulator | Differentiation antagonizing non-protein coding RNA (DANCR) | |
| Regulated Target | Urokinase-type plasminogen activator (PLAU) | |
| Crosstalk relationship | m6A → ncRNA | |
| Disease | Bladder cancer | |